Friday 6 November 2026 Export UTHR’s income statement to Excel — free account

United Therapeutics Corporation

UTHR Healthcare Drug Manufacturers Specialty & Generic

United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.

Revenue: +4.13%
EPS: −21.7%
Free cash flow: −63.7%

Quarter to September 2026, against a year earlier

564.88 43.61 −7.17%

Follow UTHR

Alert me

Market cap: $24.3B
P/E: 19.7×
Fwd P/E: 22.5×
Dividend yield: —
F-score: 8/9
Altman Z: 19.55
Beneish M: −2.26
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

United Therapeutics Corporation (UTHR) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by products and services, and margins
Tyvaso DPI	1,293	40.61%
Nebulized Tyvaso	586	18.40%
Remodulin	527	16.55%
Orenitram	497	15.61%
Unituxin	227	7.13%
Adcirca	30	0.94%
Other	24	0.75%
Gross margin		87.92%
Operating margin		46.89%
Pre-tax margin		53.85%

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2020	FY2019	FY2018	FY2017	FY2016
Tyvaso DPI	1,293 40.61%	1,034 35.92%	731 31.41%	158 8.18%	—	—	—	—	—
Nebulized Tyvaso	586 18.40%	587 20.39%	503 21.59%	715 36.91%	—	—	—	—	—
Remodulin	527 16.55%	538 18.70%	495 21.26%	500 25.83%	517 34.83%	587 40.52%	599 36.80%	671 38.89%	602 37.67%
Orenitram	497 15.61%	434 15.09%	359 15.44%	325 16.79%	293 19.76%	225 15.55%	205 12.60%	186 10.77%	157 9.83%
Unituxin	227 7.13%	239 8.30%	199 8.55%	183 9.45%	123 8.29%	114 7.85%	85 5.21%	76 4.41%	63 3.91%
Adcirca	30 0.94%	24 0.83%	29 1.24%	41 2.13%	67 4.54%	107 7.40%	324 19.89%	420 24.33%	372 23.28%
Other	24 0.75%	22 0.77%	12 0.51%	14 0.71%	0 0.00%	—	—	—	—
Product	—	—	—	—	—	—	1,628	1,725	1,599
Total Tyvaso	1,878	1,620	1,234	873	—	—	—	—	—
Revenue	3,183	2,877	2,328	1,936	1,483	1,449	1,628	1,725	1,599

Gross profit by product or service $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2020	FY2019	FY2018	FY2017	FY2016
Tyvaso DPI	‡	‡	‡	‡	‡	‡	‡	‡	‡
Remodulin	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other	‡	‡	‡	‡	‡	‡	‡	‡	‡
Orenitram	‡	‡	‡	‡	‡	‡	‡	‡	‡
Nebulized Tyvaso	‡	‡	‡	‡	‡	‡	‡	‡	‡
Unituxin	‡	‡	‡	‡	‡	‡	‡	‡	‡
Adcirca	‡	‡	‡	‡	‡	‡	‡	‡	‡
Total Tyvaso	‡	‡	‡	‡	‡	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011
U.S.	3,037 95.42%	2,740 95.21%	2,202 94.62%	1,814 93.69%	1,564 92.80%	1,412 95.20%	1,323 91.33%	1,528 93.88%	1,537 89.07%	1,462 91.44%	1,353 92.30%	1,181 91.64%	1,032 92.43%	847 92.42%	677 91.09%
ROW	146 4.58%	138 4.79%	125 5.38%	122 6.31%	121 7.20%	71 4.80%	126 8.67%	100 6.12%	189 10.93%	137 8.56%	113 7.70%	108 8.36%	85 7.57%	69 7.58%	66 8.91%
Revenue	3,183	2,877	2,328	1,936	1,686	1,483	1,449	1,628	1,725	1,599	1,466	1,289	1,117	916	743

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.